Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297309 | 0.84 | ABL1 (0.52) | CHRM2HSD17B10 | |
| SCHEMBL3296851 | 0.82 | SIGMAR1 (0.46) | OPRM1OPRK1SIGMAR1CHRM2CHRM4 | |
| SCHEMBL3302221 | 0.77 | MAPT (0.52) | OPRM1OPRK1SIGMAR1CHRM2CHRM4 | |
| SCHEMBL771596 | 0.71 | CYP3A4 (0.41) | OPRK1SIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL12881261 | 0.71 | DPP4 (0.41) | OPRM1OPRK1SIGMAR1DRD2DRD4 | |
| SCHEMBL5127061 | 0.70 | SMN1; SMN2 (0.47) | MEN1KMT2A | |
| SCHEMBL25566963 | 0.70 | KDM1A (0.47) | OPRM1SIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL3405118 | 0.70 | OPRM1 (0.52) | OPRM1SIGMAR1HRH3CYP3A4HSD17B10 | |
| SCHEMBL1203078 | 0.70 | DRD2 (0.41) | OPRK1SIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL1904970 | 0.70 | OPRM1 (0.42) | OPRM1OPRK1SIGMAR1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | claimed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | claimed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-8809365-B2 | 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders | UNIVERSITEIT GENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2610256-A1 | Pyrimidine derivatives as protein kinase inhibitors | Cyclacel Limited (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-8389561-B2 | Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions | UNIVERSITEIT GENT (BE) | 2013-03-05 | — | — | US | disclosed |
| US-8389561-B2 | Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions | UNIVERSITEIT GENT (BE) | 2013-03-05 | — | — | US | disclosed |
| US-20120245196-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1] HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | UNIVERSITEIT GENT (BE) | 2012-09-27 | — | — | US | disclosed |
| EP-2496579-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1]HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | Universiteit Gent (BE) | 2012-09-12 | — | — | EP | disclosed |
| US-20110039106-A1 | TRANSPORTER FORM FOR BASE METAL PARTICLES AND USE THEREOF | ECKA GRANULATE GMBH & CO. KG (DE) | 2011-02-17 | — | — | US | disclosed |
| US-7884125-B2 | 7-benzyl-7-azabicyclo[2.2.1]hept-1-ylmethyl)-pyridin-2-yl-amine, used for the treatment of diseases mediated by Nicotinic Acetylcholine Receptors, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and drug addiction | UNIVERSITEIT GENT (BE) | 2011-02-08 | — | — | US | disclosed |
| US-7884112-B2 | Glycogen phosphorylase inhibitor; antidiabetic agents; hypoglycemic agents; hypercholesterolemia; hypotensive agents; antilipemic agents; hypotensive agents; antiischemic agents | BRADLEY STUART EDWARD | 2011-02-08 | — | — | US | disclosed |
| US-7884125-B2 | 7-benzyl-7-azabicyclo[2.2.1]hept-1-ylmethyl)-pyridin-2-yl-amine, used for the treatment of diseases mediated by Nicotinic Acetylcholine Receptors, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and drug addiction | UNIVERSITEIT GENT (BE) | 2011-02-08 | — | — | US | disclosed |
| WO-2010119222-A1 | DERIVATIVES OF N-[(7-AZA-BICYCLO[2.2.1]HEPT-1-YL)-ARYL-METHYL]-BENZAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-21 | — | — | WO | disclosed |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20090275616-A1 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES | UNIVERSITEIT GENT (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275616-A1 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES | UNIVERSITEIT GENT (BE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093807-A1 | SUBSTITUTED 7-AZABICYCLO[2.2.1]HEPTYL DERIVATIVES USEFUL FOR MAKING PHARMACEUTICAL COMPOSITIONS | CHRNA7, CHRNA5, CHRNA6 | OPRM1 43/4885OPRK1 30/4885SIGMAR1 364/4885 |
| US-20120245196-A1 | 1-SUBSTITUTED 2-AZABICYCLO [3.1.1] HEPTYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS FOR TREATING NEUROLOGIC DISORDERS | CHRNA2, CHRNA10, CHRNA3 | OPRM1 39/4885OPRK1 31/4885SIGMAR1 335/4885 |
| US-20090275616-A1 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES | CHRNA5, CHRNA7, CHRNA2 | OPRM1 182/4885OPRK1 83/4885SIGMAR1 576/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | OPRM1 4644/4885OPRK1 3187/4885SIGMAR1 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.